Propranolol in the treatment of problematic infantile hemangiomas.
10.3969/j.issn.1672-7347.2011.11.012
- Author:
Jianyun LU
1
;
Guizhi QIN
;
Jinhua HUANG
;
Suo LI
;
Jing ZHAO
;
Yaping XIANG
;
Jing CHEN
;
Chengxin ZUO
;
Shengbo YANG
;
Lina TNA
Author Information
1. Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
- Publication Type:Clinical Trial
- MeSH:
Female;
Hemangioma;
drug therapy;
Humans;
Infant;
Male;
Propranolol;
therapeutic use;
Prospective Studies;
Skin Neoplasms;
drug therapy;
Subcutaneous Tissue
- From:
Journal of Central South University(Medical Sciences)
2011;36(11):1102-1105
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the short-term efficacy and safety of propranolol for problematic infantile hemangiomas.
METHODS:Oral propranolol was administered to 68 infants with heamngiomas diagnosed by clinical evaluation and adjuvant examination at 1.0~2.0 mg per kilogram of body weight per day, divided to 2 or 3 times. The patients revisited once a month. The changes of the tumor size, texture, and color were monitored and recorded at a regular interval.The adverse effects after medication were observed and managed accordingly.The short-term results were evaluated using a 4-grade system.
RESULTS:All the 68 infants were followed up for 3-13 months, except that 1 infants combined with other diseases and 4 withdrew.The overall response was Scale 1 in 8 infants, Scale II in 13, Scale III in 29, and Scale IV in 13. No serious adverse effects were seen, but none cured entirely as well.
CONCLUSION:Oral propranolol is safe and effective for infantile heamngioma with good short-term result. It could be used as the primary drug for problematic infantile hemangiomas at the rapid growth stage of hemangiomas.
